Ignite Creation Date:
2024-05-05 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00511888
Status:
TERMINATED
Last Update Posted:
2008-10-17
First Post:
2007-08-03
Brief Title:
Nebivolol Versus Carvedilol in Patients With Heart Failure
Sponsor:
IRCCS San Raffaele
Organization:
IRCCS San Raffaele
Study Overview
Official Title:
Effects of Nebivolol Versus Carvedilol in Hypertensive Patients With Chronic Heart Failure
Status:
TERMINATED
Status Verified Date:
2007-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
is finish
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
BACKGROUND Beta-blockers improve left ventricular LV systolic function and prognosis in patients with chronic heart failure Both carvedilol and nebivolol have hemodynamic and clinical benefits in chronic heart failure CHF but it is unknown whether their pleiotropic properties may play a role in different subgroups of patients with CHF
OBJECTIVE To compare the effects of nebivolol and carvedilol on LV function and clinical outcome in patients with chronic heart failure and reduced LV systolic function
METHODS 160 hypertensive CHF patients LV ejection fraction EF 40 and in New York Heart Association NYHA functional class II or III were randomly assigned to receive carvedilol or nebivolol therapy for 24 months At baseline and after 24 months of treatment all patients underwent clinical evaluation echocardiogram and 6-minute walking test
OBJECTIVE To compare the effects of nebivolol and carvedilol on LV function and clinical outcome in patients with chronic heart failure and reduced LV systolic function
METHODS 160 hypertensive CHF patients LV ejection fraction EF 40 and in New York Heart Association NYHA functional class II or III were randomly assigned to receive carvedilol or nebivolol therapy for 24 months At baseline and after 24 months of treatment all patients underwent clinical evaluation echocardiogram and 6-minute walking test
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None